Ernexa Therapeutics Inc. has successfully completed its second closing of a private placement, raising approximately $6.0 million in gross proceeds. The company issued an aggregate of 47,717,087 shares of common stock and 9,332,000 pre-funded warrants. This follows an initial closing where Ernexa sold 9,934,016 shares of common stock and 509,736 pre-funded warrants. In total, the private placement has resulted in gross proceeds of around $7.0 million, bolstering the company's stockholders' equity to over $2.5 million. This move is part of Ernexa's strategy to comply with Nasdaq's continued listing requirements. The net proceeds from the issuance are intended for general working capital purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.